Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...4546474849505152535455...7475»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Atrophy associated with amd after antiangiogenic therapy () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_674;    
    In NE, cRORA and cORA were correlated with worse BCVA. MA rate in FE was lower than in NE.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Clinical outcome of switching from ranibizumab to aflibercept in the treatment of neovascular age-related macular degeneration () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_665;    
    Our data so far has not shown a statistically significant result, which could be due to the small sample size, affecting the statistical power. Our Results at the large DGH is in concordance with other studies, longitudinal data tends to show more promising Results particularly in BCVA improvement.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Spontaneous and treatment induced retinal pigment epithelium(RPE) tear in exudative age-related macular degeneration () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_663;    
    Retinal pigment epithelium (RPE) tear in exudative age-related macular degeneration may occur spontaneously or after intravitreal anti-VEGF injections. Despite RPE tear is a devastating complication, continuing the treatment has crucial importance in preventing further visual loss.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Outcomes and factors to consider before switching anti-VEGF therapy in neovascular AMD () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_660;    
    Though anatomical success on OCT was seen on switching ,there was no statistically significant improvement in the visual acuity (p > 0.05) but it did show significant decrease in the mean number of injections when switched to Aflibercept.The factors to consider before switching are the presence of hyperdynamic neovascular membrane with persistent lesion activity despite high retreatment frequency, Is the patient being monitored frequently enough ? ( that is 8 weeks versus 4 weeks), identifying polyps outside the central macular area as this would be beneficial because photodynamic therapy (PDT) along with anti-VEGF agent shows synergistic effect,In pseudophakic patients rule out late onset pseudophakic cystoid macular oedema after an uneventful cataract surgery rather than underlying active neovascular membrane with a FFA , consider fibrosis of neovascular membrane, consider irreversible Retinal Pigment Epithelial changes.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Aflibercept treatment for neovascular age related macular degeneration resistant to ranibizumab () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_652;    
    ( that is 8 weeks versus 4 weeks), identifying polyps outside the central macular area as this would be beneficial because photodynamic therapy (PDT) along with anti-VEGF agent shows synergistic effect,In pseudophakic patients rule out late onset pseudophakic cystoid macular oedema after an uneventful cataract surgery rather than underlying active neovascular membrane with a FFA , consider fibrosis of neovascular membrane, consider irreversible Retinal Pigment Epithelial changes. Aflibercept treatment could be beneficial in some patients with neovascular AMD who were resistant to Ranibizumab intravitreal injections and who had persistent intraretinal and/or subretinal fluid.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    A new model for management of intravitreal injection (IVI): Bari Policlinico real-world experience () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_650;    
    Then, the patient received IVI of ranibizumab or aflibercept.Results : Among 1795 eyes treated during the first year of activity of new IVI Center, 310 eyes naïve with nAMD were selected... A diagnostic and therapeutic center dedicated only to IVI seemed to be useful in the management of nAMD, improving the functional and anatomic outcome after IVI and the patients’ compliance too.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retinal vessel analysis on octa immediately after anti-VEGF intravitreal injection () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_649;    
    The drugs administered were ranibizumab (55.1%) and aflibercept (44.9%)... after the IOP rise caused by IVI, vessel density in SCP and RNFL peripapillary thickness reduced, but neovascular membranes VD, despite their thin wall, did not statistically vary.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_645;    
    Nonvitrectomizedpatients resistant to monthly (Q4W) ranibizumab/bevacizumab wereswitched to 2 mg aflibercept every 8 weeks. Intravitreal high-dose high-frequency aflibercept is an effective treatmentfor patients with refractory wet age-related macular degeneration.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Exudative AMD and anti VEGF therapy in real life setting: clinical results and quality of treatment. () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_639;    
    According to the choices of the retinologists, the therapeutical approach was different, as the re-treatment decisions or the switches were done according to various criteria. This study represents an effective picture of the real life, where clinical approach of everyone is not always understood or shared.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Evaluation of pain during intravitreal ranibizumab injections () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_638;    
    This study represents an effective picture of the real life, where clinical approach of everyone is not always understood or shared. The pain associated with intravitreal ranibizumab injections and demonstrated that pain associated with intravitreal ranibizumab injections is generally mild and can be ignored.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
    Retrospective data, Review, Journal:  Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review. (Pubmed Central) -  Sep 25, 2019   
    Pooled evidence suggests that both IVC and IVR are effective in the therapy of diabetic macular edema and affirms that IVC presents superiority over IVR therapy in regard of CMT in patients with diabetic macular edema, but no statistically significant difference with regard to visual improvement. Relevant RCTs with longer-term follow-up are necessary to back up our conclusion.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Intravitreal Ranibizumab (Lucentis (clinicaltrials.gov) -  Sep 22, 2019   
    P2,  N=13, Completed, 
    Relevant RCTs with longer-term follow-up are necessary to back up our conclusion. Active, not recruiting --> Completed | N=10 --> 13 | Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment change, Trial completion date, Trial termination:  Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) -  Sep 19, 2019   
    P2/3,  N=5, Terminated, 
    Active, not recruiting --> Terminated; insufficient enrollment N=110 --> 5 | Trial completion date: May 2018 --> Dec 2018 | Not yet recruiting --> Terminated; study protocol changed
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment open:  COVERT: Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab (clinicaltrials.gov) -  Sep 19, 2019   
    P4,  N=168, Recruiting, 
    N=110 --> 5 | Trial completion date: May 2018 --> Dec 2018 | Not yet recruiting --> Terminated; study protocol changed Not yet recruiting --> Recruiting
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Central retinal vein occlusion associated with use of tranexamic acid () -  Sep 16, 2019 - Abstract #ESCRS2019ESCRS_2176;    
    Blood vessel occlusion including CRVO can be a side effect of tranexamic acid particularly if it exceeds the maximum recommended daily dose or if it is used for prolonged period, especially in hematological disorder patients. Early diagnosis and management of CRVO secondary to tranexamic acid will give a better outcome as seen in our case.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Strategies of Intravitreal Injections with Anti-VEGF: "Pro re Nata versus Treat and Extend" (Pubmed Central) -  Sep 14, 2019   
    The PRN regime requires frequent clinic visits to monitor disease status and intravitreal treatment if needed in a reactive approach. Individualised T&E regimens can improve visual outcome and require fewer injections than those administered in a monthly regimen and fewer monitoring visits than those in a PRN regimen.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Journal:  Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. (Pubmed Central) -  Sep 14, 2019   
    Conversely, increasing baseline aqueous VEGF was associated with a less favorable SD-OCT MV response at 3 months (every additional 100 pg/mL of baseline VEGF was associated with an increase of 0.0731 mm3; P = .02) and was associated with lower odds of being a central subfield thickness responder (odds ratio, 0.868; 95% CI, 0.755-0.998). Elevated aqueous ICAM-1 and reduced VEGF levels at baseline are associated with a favorable anatomic response to ranibizumab in DME, although there is not always direct correlation between anatomic and visual acuity response.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti. (Pubmed Central) -  Sep 11, 2019   
    Elevated aqueous ICAM-1 and reduced VEGF levels at baseline are associated with a favorable anatomic response to ranibizumab in DME, although there is not always direct correlation between anatomic and visual acuity response. No abstract available
  • ||||||||||  Trial completion, Phase classification:  Photobiomodulation for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) -  Sep 10, 2019   
    P1,  N=16, Completed, 
    With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated. Withheld --> Completed | Phase classification: PN/A --> P1
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Retinal Vein Occlusion - Which Treatment When? (Pubmed Central) -  Sep 8, 2019   
    There is evidence that early targeted laser coagulation of ischemic retina may reduce the frequency of necessary injections and improve the response of the oedema to therapy. Significant retinal ischemia may lead to proliferations, rubeosis iridis and secondary glaucoma and therefore requires laser treatment.